Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Paulden

Showing results (21-30 of 78) with videos related to

Pageof 8
Sort By:
Pharmacoeconomics|December 13, 2016
Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and MedicineMike Paulden, James F O'Mahony, Christopher McCabe
Pharmacoeconomics|March 23, 2016
Cancer Drugs Fund 2.0: A Missed Opportunity?Christopher McCabe, Ash Paul, Greg Fell, et al.
BMJ (Clinical Research Ed.)|December 24, 2009
Screening for postnatal depression in primary care: cost effectiveness analysisMike Paulden, Stephen Palmer, Catherine Hewitt, et al.
Pharmacoeconomics|November 22, 2014
Value-based reimbursement decisions for orphan drugs: a scoping review and decision frameworkMike Paulden, Tania Stafinski, Devidas Menon, et al.
Pharmacoeconomics|May 11, 2017
A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness ModelsChase Hollman, Mike Paulden, Petros Pechlivanoglou, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 19, 2025
Return-on-Investment in Health Economic Evaluation: An Exploratory AnalysisMina Alizadehsadrdaneshpour, Jacob Smith, Mike Paulden, et al.
International Journal of Technology Assessment in Health Care|July 10, 2025
A systematic review of health economic evaluation quality assessment instruments for medical devicesIlke Akpinar, Ali Unsal, Mike Paulden, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 30, 2026
Response to "Concept or Calculation?" Reassessing the Foundations of ROI Thresholds in Health Economic EvaluationMina Alizadehsadrdaneshpour, Jacob Smith, Mike Paulden, et al.
Pharmacoeconomics|November 22, 2014
Objectivity and equity: clarity required. A response to Hill and OlsonMike Paulden, James F O'Mahony, Anthony J Culyer, et al.
Pharmacoeconomics|November 23, 2020
Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit FrontierChristopher McCabe, Giovanni Tramonti, Andrew Sutton, et al.
Pageof 8

Showing results (21-30 of 78) with videos related to

Sort By:
Pageof 8
Pharmacoeconomics|December 13, 2016
Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and MedicineMike Paulden, James F O'Mahony, Christopher McCabe
Pharmacoeconomics|March 23, 2016
Cancer Drugs Fund 2.0: A Missed Opportunity?Christopher McCabe, Ash Paul, Greg Fell, et al.
BMJ (Clinical Research Ed.)|December 24, 2009
Screening for postnatal depression in primary care: cost effectiveness analysisMike Paulden, Stephen Palmer, Catherine Hewitt, et al.
Pharmacoeconomics|November 22, 2014
Value-based reimbursement decisions for orphan drugs: a scoping review and decision frameworkMike Paulden, Tania Stafinski, Devidas Menon, et al.
Pharmacoeconomics|May 11, 2017
A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness ModelsChase Hollman, Mike Paulden, Petros Pechlivanoglou, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 19, 2025
Return-on-Investment in Health Economic Evaluation: An Exploratory AnalysisMina Alizadehsadrdaneshpour, Jacob Smith, Mike Paulden, et al.
International Journal of Technology Assessment in Health Care|July 10, 2025
A systematic review of health economic evaluation quality assessment instruments for medical devicesIlke Akpinar, Ali Unsal, Mike Paulden, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 30, 2026
Response to "Concept or Calculation?" Reassessing the Foundations of ROI Thresholds in Health Economic EvaluationMina Alizadehsadrdaneshpour, Jacob Smith, Mike Paulden, et al.
Pharmacoeconomics|November 22, 2014
Objectivity and equity: clarity required. A response to Hill and OlsonMike Paulden, James F O'Mahony, Anthony J Culyer, et al.
Pharmacoeconomics|November 23, 2020
Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit FrontierChristopher McCabe, Giovanni Tramonti, Andrew Sutton, et al.
Pageof 8